NCT04063826 (iDOSH) is a NA clinical trial of PET MRI in Steatohepatitis, sponsored by Imperial College London.

Who is sponsoring NCT04063826?

NCT04063826 is sponsored by Imperial College London.

What drugs are being tested in NCT04063826?

Interventions in NCT04063826: PET MRI.

What condition does NCT04063826 study?

NCT04063826 studies Steatohepatitis.

Is NCT04063826 still recruiting?

NCT04063826 is currently status unknown. Last updated 9 November 2023.

Last reviewed 2023-11-09 · How we verify

NCT04063826: iDOSH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PET-MR Study of Fatty Liver

Status unknown NA Last updated 9 November 2023

What this trial tests

NA trial testing PET MRI in Steatohepatitis in 10 participants. Status unknown.

Timeline

10 April 2018

Primary endpoint
28 February 2020

31 December 2023

Quick facts

Lead sponsor	Imperial College London
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	10
Start date	10 April 2018
Primary completion	28 February 2020
Estimated completion	31 December 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

PET MRI

Conditions studied

Steatohepatitis — all drugs for Steatohepatitis →

Sponsor

Imperial College London

Who can join

Adults 18 to 100, any sex, with Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot, translational study designed to explore the feasibility of molecular imaging with FBA-A20FMDV2, radiolabelled with fluorine-18 (\[18F\]-FBA-A20FMDV2), in patients with SH and CASH in hepatic metastatic disease. FBA-A20FMDV2, a synthetic peptide derived from the foot and mouth disease virus (FMDV), has been shown pre-clinically to specifically bind to the epithelial specific integrin αvβ6 which is known to be overexpressed in tumours. In this study, we aim to evaluate the uptake of \[18F\]-FBA-A20FMDV2 (\[18F\]-IMAFIB) in patients with SH and CASH in CRC hepatic metastatic disease using PET. Up to ten subjects will undergo \[18F\]-FBA-A20FMDV-PET scanning. An adaptive study design will enable us to determine the optimal imaging protocol for future studies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Integrins and NAFLD-associated liver diseases: clinical associations, pathophysiological mechanisms and pharmacological implications.
Ni Y, Huang M, Chen S, Wang S, et al · · 2024 · cited 2× · PMID 40384047 · DOI 10.3724/abbs.2024149

Verify or expand the search:

Other trials of PET MRI

Trials testing the same drug.

NCT03369288 — Assessing Cement-bone Incorporation and Adjacent Segment Degeneration Following Cement Augmentation; an MRI-PET Follow-u · NA · unknown

Other recruiting trials for Steatohepatitis

Currently open trials in the same condition.

NCT07476703 — Expanded Studies on the SCAPIS Stockholm Reexamination Cohort · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04063826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04063826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing